Overview
Xtandi is approved by the U.S. Food and Drug Administration (FDA) to treat several forms of prostate cancer, including castration-resistant prostate cancer (CRPC), metastatic castration-sensitive prostate cancer (mCSPC), and nonmetastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk for metastasis (spreading to other parts of the body). People with CRPC or mCSPC should also receive a gonadotropin-releasing hormone (GnRH) analog when taking Xtandi or have had orchiectomy (surgical removal of the testes). Xtandi is also known by its drug name, enzalutamide.

Xtandi is an androgen receptor inhibitor. It works by blocking the effects of androgens (sex hormones such as testosterone), which can fuel the growth of prostate cancer cells.

How do I take it?
Prescribing information states that Xtandi is taken orally once daily, with or without food. It is available in capsule or tablet form and should be swallowed whole with water. Xtandi should be taken exactly as prescribed by a healthcare provider.

Side effects
Common side effects of Xtandi include musculoskeletal pain, fatigue, hot flushes, constipation, decreased appetite, diarrhea, hypertension (high blood pressure), hemorrhage (bleeding), falls, bone fractures, and headaches.

Rare but serious side effects may include seizures, posterior reversible encephalopathy syndrome (a rare brain condition causing headache, confusion, and vision problems), hypersensitivity (severe allergic reactions), ischemic heart disease (reduced blood flow to the heart), and embryo-fetal toxicity (risk of harm to an unborn baby). Xtandi may also cause swallowing difficulties due to the size of the tablets or capsules.

For more information about this treatment, visit:
Xtandi (Enzalutamide) Capsules, for Oral Use; Xtandi (Enzalutamide) Tablets, for Oral Use — Astellas Pharma US